--- title: "CERo Therapeutics Holdings (CERO) news: delisting" url: "https://aibio.space/companies/cero-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CERO delisting and convertible notes news: CERo Therapeutics appeals Nasdaq delisting over $2,500,000 stockholders' equity rule." --- CERO CERo Therapeutics Holdings, Inc. OTC · United States # CERo Therapeutics Holdings (CERO) news CERO delisting and convertible notes news Debt Financing · 2026-10-07 ## [CERo agrees to sell operating unit to SRX Global](https://aibio.space/news/cero-agrees-sell-operating-unit-srx-global/) CERo Therapeutics Holdings agreed on October 6, 2026 to sell its operating subsidiary to SRX Global Inc. The buyer would discharge the Consolidated Note, which had an outstanding principal balance of $8,249,643.77. ## Latest CERo Therapeutics Holdings news 1. 2026-08-27 Debt Financing [CERo Therapeutics consolidates older notes into secured SRX Global loan](https://aibio.space/news/cero-therapeutics-consolidates-older-notes-secured-srx-global-loan/) The note combines earlier notes and lets SRX advance up to $6,000,000 in total at 10% interest. Principal and interest are due October 15, 2026. 2. 2026-07-14 Debt Financing [CERo Therapeutics expands SRX Global convertible note to $2,085,200](https://aibio.space/news/cero-therapeutics-expands-srx-global-convertible-note-2-085-200/) CERo Therapeutics expanded its convertible note with SRX Global to $2,085,200. The note carries 10% interest, matures May 28, 2027, and converts at the lesser of $0.05 and 80% of recent trading lows. 3. 2026-06-23 Debt Financing [CERo Therapeutics amends $1,413,600 promissory note with SRX Health](https://aibio.space/news/cero-therapeutics-amends-1-413-600-promissory-note-srx-health/) CERo Therapeutics amended a note with SRX Health Solutions, Inc. that converts into common stock at a price set by recent trading. The maximum is $1,413,600, of which $663,600 was funded on June 23, 2026. 4. 2026-05-28 Debt Financing [CERo Therapeutics issues $937,500 convertible note to SRX Health Solutions](https://aibio.space/news/cero-therapeutics-issues-937-500-convertible-note-srx-health-solutions/) The note was sold for $750,000 and bears 10% interest, with conversion at the lesser of $0.05 or a discount to recent trading prices. 5. 2026-05-01 Debt Financing [CERo sells convertible note with $500,000 face value to Keystone](https://aibio.space/news/cero-sells-convertible-note-500-000-face-value-keystone/) CERo Therapeutics Holdings issued a convertible promissory note to Keystone Capital Partners, LLC on April 27, 2026, with a purchase price of $400,000 and a principal face value of $500,000. 6. 2025-09-04 Listings [CERo Therapeutics appeals Nasdaq delisting over $2,500,000 stockholders' equity rule](https://aibio.space/news/cero-therapeutics-appeals-nasdaq-delisting-2-500-000-stockholders/) Nasdaq staff set a September 8, 2025 delisting date. CERo requested a hearing on September 3, 2025, which stays the suspension, and plans to present a compliance plan. 7. 2025-08-15 Distress [CERo Therapeutics delays Q2 report, estimates $18.5 million quarterly net loss](https://aibio.space/news/cero-therapeutics-delays-q2-report-estimates-18-5-million-quarterly/) The company needs more time to value marketable securities it received as part payment for Series D Preferred Stock. It estimates an $18.5 million net loss for the quarter and a $33.4 million loss attributable to common shareholders. 8. 2025-04-22 Financings [CERo Therapeutics signs up to $8 million Series D convertible preferred financing](https://aibio.space/news/cero-therapeutics-signs-up-8-million-series-d-convertible-preferred/) About $5 million is expected at the first closing. The company said the money will also help address Nasdaq shareholders' equity deficiencies. ## CERo Therapeutics Holdings at a glance - **Ticker**: CERO - **Listing**: OTC - **Country**: United States - **Cash, Jun 30, 2026**: $862,756 ### Related companies - [PaxMedica](https://aibio.space/companies/paxmedica/) OTC: PXMD - [Climb Bio](https://aibio.space/companies/climb-bio/) NASDAQ: CLYM - [Prelude Therapeutics](https://aibio.space/companies/prelude-therapeutics/) NASDAQ: PRLD - [Jasper Therapeutics](https://aibio.space/companies/jasper-therapeutics/) NASDAQ: JSPR - [Scribe Therapeutics](https://aibio.space/companies/scribe-therapeutics/) NASDAQ: SCTX - [VirExit Technologies](https://aibio.space/companies/virexit-technologies/) OTC: VXIT - [Statera Biopharma](https://aibio.space/companies/statera-biopharma/) OTC: STAB - [OSR Health](https://aibio.space/companies/osr-health/) OTC: OSRH ### Also on OTC - [Mosaic ImmunoEngineering](https://aibio.space/companies/mosaic-immunoengineering/) CPMV - [Fresenius SE & Co. KGaA](https://aibio.space/companies/fresenius-fsnuy/) FSNUY - [Northwest Biotherapeutics](https://aibio.space/companies/northwest-biotherapeutics/) NWBO - [Nano Mobile Healthcare](https://aibio.space/companies/nano-mobile-healthcare/) VNTH - [Beroni Group](https://aibio.space/companies/beroni/) BNIGF - [LUCY SCIENTIFIC DISCOVERY INC](https://aibio.space/companies/lucy-scientific-discovery/) LSDIF ## CERo Therapeutics Holdings annual financials | Line | FY2025 | FY2023 | |---|---|---| | Research and development | | [$5.3 million](https://www.sec.gov/Archives/edgar/data/1870404/000121390025032134/) | | Net income (loss) | [-$19.9 million](https://www.sec.gov/Archives/edgar/data/1870404/000121390026044040/) | [-$7.3 million](https://www.sec.gov/Archives/edgar/data/1870404/000121390025032134/) | | Cash from operations | [-$16.1 million](https://www.sec.gov/Archives/edgar/data/1870404/000121390026044040/) | [-$1.5 million](https://www.sec.gov/Archives/edgar/data/1870404/000121390024029051/) | | Cash and equivalents | [$1.7 million](https://www.sec.gov/Archives/edgar/data/1870404/000121390026090030/) | [$96,873](https://www.sec.gov/Archives/edgar/data/1870404/000121390024029051/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $862,756. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about CERo Therapeutics Holdings Was CERo Therapeutics Holdings delisted? Our latest story on this, dated Sep 4, 2025: "CERo Therapeutics appeals Nasdaq delisting over $2,500,000 stockholders' equity rule". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cero-therapeutics-appeals-nasdaq-delisting-2-500-000-stockholders/). Has CERo Therapeutics Holdings sold convertible notes? Our latest story on this, dated Jul 14, 2026: "CERo Therapeutics expands SRX Global convertible note to $2,085,200". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cero-therapeutics-expands-srx-global-convertible-note-2-085-200/). What is the ticker symbol of CERo Therapeutics Holdings? CERo Therapeutics Holdings, Inc. trades under the ticker CERO on OTC. Where is CERo Therapeutics Holdings listed? CERo Therapeutics Holdings, Inc. is listed on OTC. What is the SEC CIK of CERo Therapeutics Holdings? The SEC Central Index Key (CIK) for CERo Therapeutics Holdings, Inc. is 1870404. Its filings are on SEC EDGAR. How many shares does CERo Therapeutics Holdings have outstanding? 71,630,992 shares as of 2026-08-13, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is CERo Therapeutics Holdings listed under? Our directory records CERo Therapeutics Holdings, Inc. under United States. What does CERo Therapeutics Holdings do? Our directory classifies CERo Therapeutics Holdings, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of CERo Therapeutics Holdings? The ISIN recorded for CERo Therapeutics Holdings, Inc. is US71902K4022. Does aibio.space cover CERo Therapeutics Holdings? aibio.space lists CERo Therapeutics Holdings, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is CERo Therapeutics Holdings incorporated? SEC records list its state or country of incorporation as DE. Is CERo Therapeutics Holdings profitable? CERo Therapeutics Holdings, Inc. reported a net loss of $19.9 million for the fiscal year ended Dec 31, 2025, and used $16.1 million of cash in operations, per its annual report to the SEC. How much cash does CERo Therapeutics Holdings have? $862,756 in cash at Jun 30, 2026, per its 10-Q. What is the latest CERo Therapeutics Holdings (CERO) stock news? Our latest story on CERo Therapeutics Holdings, dated Oct 7, 2026: "CERo agrees to sell operating unit to SRX Global". CERo Therapeutics Holdings agreed on October 6, 2026 to sell its operating subsidiary to SRX Global Inc. The buyer would discharge the Consolidated Note, which had an outstanding principal balance of $8,249,643.77. [Source](https://aibio.space/news/cero-agrees-sell-operating-unit-srx-global/). What is CERo Therapeutics Holdings's latest stock offering or financing news? Our latest financing story, dated Apr 22, 2025: "CERo Therapeutics signs up to $8 million Series D convertible preferred financing". About $5 million is expected at the first closing. The company said the money will also help address Nasdaq shareholders' equity deficiencies. [Source](https://aibio.space/news/cero-therapeutics-signs-up-8-million-series-d-convertible-preferred/). ## Investor discussion: CERo Therapeutics Holdings Members talk about CERo Therapeutics Holdings (CERO). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at CERo Therapeutics Holdings, newest first. Each line links the filing it comes from. 1. 2026-08-31 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,1.02,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390026095776/ea0304037-8k_cero.htm) 2. 2026-07-13 Listings Filed to remove its shares from exchange listing. SEC Form 25-NSE. [Source](https://www.sec.gov/Archives/edgar/data/1870404/000135445726000670/xslF25X02/primary_doc.xml) 3. 2026-04-15 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390026044040/ea0285271-10k_cero.htm) 4. 2026-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390026038509/ea0284239-nt10k_cero.htm) 5. 2026-02-13 Legal Reported a change of independent auditor. SEC Form 8-K (Items 1.01,2.03,3.02,4.01,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390026016474/ea0276984-8k_ceroa.htm) 6. 2026-02-03 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390026011587/ea0274896-8k_cero.htm) 7. 2025-12-19 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025123912/ea0270420-8k_cero.htm) 8. 2025-11-28 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025115783/ea0262220-02.htm) 9. 2025-11-17 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025111175/ea0262220-01.htm) 10. 2025-11-17 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025111295/ea0265704-nt10q_cero.htm) 11. 2025-10-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025103661/ea026303602ex99-1_cerothera.htm) 12. 2025-10-14 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025098421/ea0260318-8k_cero.htm) 13. 2025-09-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025084498/ea0255967-8k_cero.htm) 14. 2025-08-15 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025077436/ea0253093-nt10q_cero.htm) 15. 2025-07-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025061911/ea0248316-8k_cero.htm) 16. 2025-06-13 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025054371/ea0245650-8k_cero.htm) 17. 2025-06-11 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025053292/ea024532801ex99-1_cero.htm) 18. 2025-06-06 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025051750/ea024484501ex99-1_cero.htm) 19. 2025-05-29 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.02,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025048998/ea0243837-8k_cero.htm) 20. 2025-05-08 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025041063/ea024141101ex99-1_cero.htm) 21. 2025-05-07 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025040263/ea0236508-04.htm) 22. 2025-04-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.03,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025035535/ea023932101ex99-1_cero.htm) 23. 2025-04-25 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025035562/ea0236508-01.htm) 24. 2025-04-22 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025033946/ea023892501ex99-1_cerotherap.htm) 25. 2025-04-15 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025032134/ea0237245-10k_cero.htm) 26. 2025-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025026702/ea023602201-nt10k_cero.htm) 27. 2025-02-12 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025012891/ea0230890-8k_cerotherap.htm) 28. 2025-02-06 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025010731/ea023015801ex99-1_cerotherap.htm) 29. 2025-01-21 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025004756/ea0228123-8k_cerotherap.htm) 30. 2025-01-06 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1870404/000121390025001156/ea022677201ex99-1_cero.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open OTC:CERO on TradingView](https://www.tradingview.com/symbols/OTC-CERO/). ## SEC filings and registration - **SEC name**: Cero Therapeutics Holdings, Inc. - **CIK**: 1870404 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: CERO (OTC), CEROW (OTC) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 201 HASKINS WAY, SOUTH SAN FRANCISCO, CA, 94080 - **Phone**: 650-407-2376 - **Shares outstanding**: 71,630,992 as of 2026-08-13 (10-Q filed 2026-08-14) - **Former names**: CERO THERAPEUTICS HOLDINGS, INC.; PHOENIX BIOTECH ACQUISITION CORP. ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1870404/000121390026107410/ea0307733-8k_cero.htm) filed 2026-10-07 - [8-K](https://www.sec.gov/Archives/edgar/data/1870404/000121390026095776/ea0304037-8k_cero.htm) filed 2026-08-31 - [10-Q](https://www.sec.gov/Archives/edgar/data/1870404/000121390026090030/ea0301323-10q_cerotherap.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/1870404/000121390026079207/ea0298463-8k_cero.htm) filed 2026-07-17 - [8-K](https://www.sec.gov/Archives/edgar/data/1870404/000121390026072602/ea0296022-8k_cero.htm) filed 2026-06-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1870404/000121390026062802/ea0292715-8k_cero.htm) filed 2026-05-29 - [10-Q](https://www.sec.gov/Archives/edgar/data/1870404/000121390026057753/ea0290300-10q_cerotherap.htm) filed 2026-05-15 - [8-K](https://www.sec.gov/Archives/edgar/data/1870404/000121390026050951/ea028870101-8k_cero.htm) filed 2026-05-01 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001870404), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details CERo Therapeutics Holdings, Inc. is a public biotech or pharmaceutical company listed on OTC under the ticker CERO, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: CERo Therapeutics Holdings, Inc. - **Ticker**: CERO - **Listing**: OTC - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US71902K4022 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/OTC-CERO/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cero-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "CERo Therapeutics Holdings (CERO) news: delisting", 2026-10-31, https://aibio.space/companies/cero-therapeutics/